Daria Mochly-Rosen

Administrative Appointments

• Senior Associate Dean for Research, School of Medicine , (2006– present )
• Professor, Department of Chemical and Systems Biology , (2001– present )
• Chief, Division of Chemical Biology , (2001– 2002 )
• Member, Neuroscience Institute at Stanford , (2002– present )
• Chair, Department of Molecular Pharmacology , (2002– 2006 )
• Professor, by courtesy, Department of Neurosurgery , (2004– present )
• Member, Cancer Institute at Stanford , (2005– present )
• Senior Associate Dean for Research, Stanford University School of Medicine , (2006– present )

Honors and Awards

• The George D Smith Professor of Translational Medicine, School of medicine (2005)
• Reed-Hodgson Professor in Human Biology, Stanford University (1996-2001)

Professional Education

• Ph.D., Weizmann Institute, Israel Chemical Immunology (1983)
• B.S., Tel Aviv University, Israel Life Sciences (1977)

Postdoctoral Advisees

• Grant Budas, Suresh Palaniyandi, Xin Qi, Nir Qvit

Graduate & Fellowship Program Affiliations

• Cancer Biology
• Chemical and Systems Biology

Web Site Links

• Mochly-Rosen Lab Site

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. 

• Consulting: KAI Pharmaceuticals, Inc
• Equity: KAI Pharmaceuticals, Inc
• Service on Board of Directors: KAI Pharmaceuticals, Inc

Research Interests

We are studying the mechanism of protein kinase C-mediated signal transduction in several disease models. Based on our recent data, we proposed a working hypothesis that activated PKC isozymes bind to intracellular receptor proteins located at different subcellular sites, and that these receptors differentially bind specific PKC isozymes. Evidence was obtained for the presence of intracellular receptor proteins that bind activated PKC. Binding of PKC to these proteins was concentration-dependent, saturable and specific, suggesting that these binding proteins are receptors for activated C-kinase, or "RACKs".

We have characterized and cloned several RACKs and identified domains in different PKC isozymes that are required for the specific association with these RACKs; these domains are distinct from the substrate binding site on PKC. On the basis of this information, together with computer modeling of crystal structures of the interacting proteins, we have identified novel isozyme-selective inhibitors that inhibit translocation and the consequent function of individual PKC isozymes. These inhibitors are fragments of PKC or RACKs that have 'dominant negative' activities on PKC binding to RACKs and on their activities, in vivo. In addition, we prepared synthetic peptides corresponding to the binding sites in PKC and RACKs. We are currently determining the effects of these isozyme-selective translocation inhibitors on a number of PKC-mediated cell functions in normal and diseased heart. These include cardiac and smooth muscle cell contraction, gene expression, hypertrophy, and response to and protection from ischemic insult.

Publications

• Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Kim J,  Choi YL, Vallentin A, Hunrichs BS, Hellerstein MK, Peehl DM, Mochly-Rosen D.  Cancer Res.  2008; 68 (16): 6831-9
• Sustained pharmacological inhibition of deltaPKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats. Qi X,  Inagaki K, Sobel RA, Mochly-Rosen D.  J Clin Invest.  2008; 118 (1): 173-82
• Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Chen CH,  Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D.  Science.  2008; 321 (5895): 1493-5
• RBCK1, a protein kinase CbetaI (PKCbetaI)-interacting protein, regulates PKCbeta-dependent function. Vallentin A,  Mochly-Rosen D.  J Biol Chem.  2007; 282 (3): 1650-7
• Peptides derived from the C2 domain of protein kinase C epsilon (epsilon PKC) modulate epsilon PKC activity and identify potential protein-protein interaction surfaces. Brandman R,  Disatnik MH, Churchill E, Mochly-Rosen D.  J Biol Chem.  2007; 282 (6): 4113-23
• Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage. Ikeno F,  Inagaki K, Rezaee M, Mochly-Rosen D.  Cardiovasc Res.  2007; 73 (4): 699-709
• Protein kinase C delta (deltaPKC)-annexin V interaction: a required step in deltaPKC translocation and function. Kheifets V,  Bright R, Inagaki K, Schechtman D, Mochly-Rosen D.  J Biol Chem.  2006; 281 (32): 23218-26
• Reperfusion-induced translocation of deltaPKC to cardiac mitochondria prevents pyruvate dehydrogenase reactivation. Churchill EN,  Murriel CL, Chen CH, Mochly-Rosen D, Szweda LI.  Circ Res.  2005; 97 (1): 78-85
• Cardioprotection by epsilon-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase C-activating peptide. Inagaki K,  Begley R, Ikeno F, Mochly-Rosen D.  Circulation.  2005; 111 (1): 44-50
• Ethanol withdrawal-associated allodynia and hyperalgesia: age-dependent regulation by protein kinase C epsilon and gamma isoenzymes. Shumilla JA,  Liron T, Mochly-Rosen D, Kendig JJ, Sweitzer SM.  J Pain.  2005; 6 (8): 535-49
• A critical intramolecular interaction for protein kinase Cepsilon translocation. Schechtman D,  Craske ML, Kheifets V, Meyer T, Schechtman J, Mochly-Rosen D.  J Biol Chem.  2004; 279 (16): 15831-40
• Protein kinase C delta mediates cerebral reperfusion injury in vivo. Bright R,  Raval AP, Dembner JM, Pérez-Pinzón MA, Steinberg GK, Yenari MA, Mochly-Rosen D.  J Neurosci.  2004; 24 (31): 6880-8
• Protein kinase Cdelta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. Murriel CL,  Churchill E, Inagaki K, Szweda LI, Mochly-Rosen D.  J Biol Chem.  2004; 279 (46): 47985-91
• Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Inagaki K,  Chen L, Ikeno F, Lee FH, Imahashi K, Bouley DM, Rezaee M, Yock PG, Murphy E, Mochly-Rosen D.  Circulation.  2003; 108 (19): 2304-7
• Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Inagaki K,  Hahn HS, Dorn GW, Mochly-Rosen D.  Circulation.  2003; 108 (7): 869-75
• Molecular dynamics characterization of the C2 domain of protein kinase Cbeta. Banci L,  Cavallaro G, Kheifets V, Mochly-Rosen D.  J Biol Chem.  2002; 277 (15): 12988-97
• Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chen L,  Wright LR, Chen CH, Oliver SF, Wender PA, Mochly-Rosen D.  Chem Biol.  2001; 8 (12): 1123-9
• Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Chen L,  Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW, Mochly-Rosen D.  Proc Natl Acad Sci U S A.  2001; 98 (20): 11114-9
• Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C. Stebbins EG,  Mochly-Rosen D.  J Biol Chem.  2001; 276 (32): 29644-50
• Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Mochly-Rosen D,  Wu G, Hahn H, Osinska H, Liron T, Lorenz JN, Yatani A, Robbins J, Dorn GW.  Circ Res.  2000; 86 (11): 1173-9
• Cardioprotection from ischemia by a brief exposure to physiological levels of ethanol: role of epsilon protein kinase C. Chen CH,  Gray MO, Mochly-Rosen D.  Proc Natl Acad Sci U S A.  1999; 96 (22): 12784-9
• Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Dorn GW,  Souroujon MC, Liron T, Chen CH, Gray MO, Zhou HZ, Csukai M, Wu G, Lorenz JN, Mochly-Rosen D.  Proc Natl Acad Sci U S A.  1999; 96 (22): 12798-803
• Peptide modulators of protein-protein interactions in intracellular signaling. Souroujon MC,  Mochly-Rosen D.  Nat Biotechnol.  1998; 16 (10): 919-24
• A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. Gray MO,  Karliner JS, Mochly-Rosen D.  J Biol Chem.  1997; 272 (49): 30945-51
• The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase Cepsilon. Csukai M,  Chen CH, De Matteis MA, Mochly-Rosen D.  J Biol Chem.  1997; 272 (46): 29200-6
• An autoregulatory region in protein kinase C: the pseudoanchoring site. Ron D,  Mochly-Rosen D.  Proc Natl Acad Sci U S A.  1995; 92 (2): 492-6
• Localization of protein kinases by anchoring proteins: a theme in signal transduction. Mochly-Rosen D,  Science.  1995; 268 (5208): 247-51
• Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. Ron D,  Chen CH, Caldwell J, Jamieson L, Orr E, Mochly-Rosen D.  Proc Natl Acad Sci U S A.  1994; 91 (3): 839-43
• Localization of protein kinase C isozymes in cardiac myocytes. Disatnik MH,  Buraggi G, Mochly-Rosen D.  Exp Cell Res.  1994; 210 (2): 287-97
• Inhibition of protein kinase C function by injection of intracellular receptors for the enzyme. Smith BL,  Mochly-Rosen D.  Biochem Biophys Res Commun.  1992; 188 (3): 1235-40
• Intracellular receptors for activated protein kinase C. Identification of a binding site for the enzyme. Mochly-Rosen D,  Khaner H, Lopez J, Smith BL.  J Biol Chem.  1991; 266 (23): 14866-8
• Chronic ethanol causes heterologous desensitization of receptors by reducing alpha s messenger RNA. Mochly-Rosen D,  Chang FH, Cheever L, Kim M, Diamond I, Gordon AS.  Nature.  1988; 333 (6176): 848-50
• Domain structure and phosphorylation of protein kinase C. Mochly-Rosen D,  Koshland DE.  J Biol Chem.  1987; 262 (5): 2291-7
• Monoclonal anti-acetylcholine-receptor antibodies directed against the cholinergic binding site. Mochly-Rosen D,  Fuchs S.  Biochemistry.  1981; 20 (20): 5920-4
• Rationally designed peptide regulators of protein kinase C. Churchill EN,  Qvit N, Mochly-Rosen D.  Trends Endocrinol Metab.  2009; 20 (1): 25-33
• Activating deltaPKC antagonizes the protective effect of ERK1/2 inhibition against stroke in rats. Castañeda D,  Zhao H, Mochly-Rosen D, Steinberg GK.  Brain Res.  2009; 1251 256-61
• Time-dependent and ethanol-induced cardiac protection from ischemia mediated by mitochondrial translocation of varepsilonPKC and activation of aldehyde dehydrogenase 2. Churchill EN,  Disatnik MH, Mochly-Rosen D.  J Mol Cell Cardiol.  2009; 46 (2): 278-84
• Preserved coronary endothelial function by inhibition of delta protein kinase C in a porcine acute myocardial infarction model. Kaneda H,  Ikeno F, Inagaki K, Mochly-Rosen D.  Int J Cardiol.  2009; 133 (2): 256-9
• Mast cells and epsilonPKC: a role in cardiac remodeling in hypertension-induced heart failure. Palaniyandi SS,  Inagaki K, Mochly-Rosen D.  J Mol Cell Cardiol.  2008; 45 (6): 779-86
• Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Inagaki K,  Koyanagi T, Berry NC, Sun L, Mochly-Rosen D.  Hypertension.  2008; 51 (6): 1565-9
• PKC isozymes in chronic cardiac disease: possible therapeutic targets? Churchill E,  Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D.  Annu Rev Pharmacol Toxicol.  2008; 48 569-99
• epsilonPKC confers acute tolerance to cerebral ischemic reperfusion injury. Bright R,  Sun GH, Yenari MA, Steinberg GK, Mochly-Rosen D.  Neurosci Lett.  2008; 441 (1): 120-4
• Alteration of gene expression during progression of hypertension-induced cardiac dysfunction in rats. Koyanagi T,  Wong LY, Inagaki K, Petrauskene OV, Mochly-Rosen D.  Am J Physiol Heart Circ Physiol.  2008; 295 (1): H220-6
• Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Budas GR,  Churchill EN, Mochly-Rosen D.  Pharmacol Res.  2007; 55 (6): 523-36
• Pharmacological inhibition of epsilon PKC suppresses chronic inflammation in murine cardiac transplantation model. Koyanagi T,  Noguchi K, Ootani A, Inagaki K, Robbins RC, Mochly-Rosen D.  J Mol Cell Cardiol.  2007; 43 (4): 517-22
• deltaPKC participates in the endoplasmic reticulum stress-induced response in cultured cardiac myocytes and ischemic heart. Qi X,  Vallentin A, Churchill E, Mochly-Rosen D.  J Mol Cell Cardiol.  2007; 43 (4): 420-8
• Mitochondrial protein kinase Cepsilon (PKCepsilon): emerging role in cardiac protection from ischaemic damage. Budas GR,  Mochly-Rosen D.  Biochem Soc Trans.  2007; 35 (Pt 5): 1052-4
• The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury. Churchill EN,  Mochly-Rosen D.  Biochem Soc Trans.  2007; 35 (Pt 5): 1040-2
• Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic. Budas GR,  Koyanagi T, Churchill EN, Mochly-Rosen D.  Biochem Soc Trans.  2007; 35 (Pt 5): 1021-6
• Insight into intra- and inter-molecular interactions of PKC: design of specific modulators of kinase function. Kheifets V,  Mochly-Rosen D.  Pharmacol Res.  2007; 55 (6): 467-76
• Suppression of deltaPKC activation after focal cerebral ischemia contributes to the protective effect of hypothermia. Shimohata T,  Zhao H, Sung JH, Sun G, Mochly-Rosen D, Steinberg GK.  J Cereb Blood Flow Metab.  2007; 27 (8): 1463-75
• DeltaPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo. Bright R,  Steinberg GK, Mochly-Rosen D.  Brain Res.  2007; 1144 146-55
• Peptide modulators of Src activity in G1 regulate entry into S phase and proliferation of NIH 3T3 cells. Mamidipudi V,  Miller LD, Mochly-Rosen D, Cartwright CA.  Biochem Biophys Res Commun.  2007; 352 (2): 423-30
• Rational design of a selective antagonist of epsilon protein kinase C derived from the selective allosteric agonist, pseudo-RACK peptide. Liron T,  Chen LE, Khaner H, Vallentin A, Mochly-Rosen D.  J Mol Cell Cardiol.  2007; 42 (4): 835-41
• Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase. Siwko S,  Mochly-Rosen D.  Int J Biochem Cell Biol.  2007; 39 (5): 978-87
• Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Inagaki K,  Churchill E, Mochly-Rosen D.  Cardiovasc Res.  2006; 70 (2): 222-30
• Protein kinase C delta cleavage initiates an aberrant signal transduction pathway after cardiac arrest and oxygen glucose deprivation. Raval AP,  Dave KR, Prado R, Katz LM, Busto R, Sick TJ, Ginsberg MD, Mochly-Rosen D, Pérez-Pinzón MA.  J Cereb Blood Flow Metab.  2005; 25 (6): 730-41
• PKC-{epsilon}-dependent survival signals in diabetic hearts. Malhotra A,  Begley R, Kang BP, Rana I, Liu J, Yang G, Mochly-Rosen D, Meggs LG.  Am J Physiol Heart Circ Physiol.  2005; 289 (4): H1343-50
• Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators. Tanaka M,  Gunawan F, Terry RD, Inagaki K, Caffarelli AD, Hoyt G, Tsao PS, Mochly-Rosen D, Robbins RC.  J Thorac Cardiovasc Surg.  2005; 129 (5): 1160-7
• Protein kinase Cgamma mediates ethanol withdrawal hyper-responsiveness of NMDA receptor currents in spinal cord motor neurons. Li HF,  Mochly-Rosen D, Kendig JJ.  Br J Pharmacol.  2005; 144 (3): 301-7
• DeltaPKC-mediated activation of epsilonPKC in ethanol-induced cardiac protection from ischemia. Inagaki K,  Mochly-Rosen D.  J Mol Cell Cardiol.  2005; 39 (2): 203-11
• The role of protein kinase C in cerebral ischemic and reperfusion injury. Bright R,  Mochly-Rosen D.  Stroke.  2005; 36 (12): 2781-90
• RSA 2004: combined basic research satellite symposium - session three: alcohol and mitochondrial metabolism: at the crossroads of life and death. Szabo G,  Hoek JB, Darley-Usmar V, Hajnoczky G, Knudsen T, Mochly-Rosen D, Zakhari S.  Alcohol Clin Exp Res.  2005; 29 (9): 1749-52
• Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts. Tanaka M,  Terry RD, Mokhtari GK, Inagaki K, Koyanagi T, Kofidis T, Mochly-Rosen D, Robbins RC.  Circulation.  2004; 110 (11 Suppl 1): II194-9
• Exaggerated nociceptive responses on morphine withdrawal: roles of protein kinase C epsilon and gamma. Sweitzer SM,  Wong SM, Tjolsen A, Allen CP, Mochly-Rosen D, Kendig JJ.  Pain.  2004; 110 (1-2): 281-9
• RACK1 regulates Src-mediated Sam68 and p190RhoGAP signaling. Miller LD,  Lee KC, Mochly-Rosen D, Cartwright CA.  Oncogene.  2004; 23 (33): 5682-6
• Cell-specific role for epsilon- and betaI-protein kinase C isozymes in protecting cortical neurons and astrocytes from ischemia-like injury. Wang J,  Bright R, Mochly-Rosen D, Giffard RG.  Neuropharmacology.  2004; 47 (1): 136-45
• Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. Begley R,  Liron T, Baryza J, Mochly-Rosen D.  Biochem Biophys Res Commun.  2004; 318 (4): 949-54
• Protein kinase C epsilon and gamma: involvement in formalin-induced nociception in neonatal rats. Sweitzer SM,  Wong SM, Peters MC, Mochly-Rosen D, Yeomans DC, Kendig JJ.  J Pharmacol Exp Ther.  2004; 309 (2): 616-25
• State-specific monoclonal antibodies identify an intermediate state in epsilon protein kinase C activation. Souroujon MC,  Yao L, Chen H, Endemann G, Khaner H, Geeraert V, Schechtman D, Gordon AS, Diamond I, Mochly-Rosen D.  J Biol Chem.  2004; 279 (17): 17617-24
• Epsilon protein kinase C mediated ischemic tolerance requires activation of the extracellular regulated kinase pathway in the organotypic hippocampal slice. Lange-Asschenfeldt C,  Raval AP, Dave KR, Mochly-Rosen D, Sick TJ, Pérez-Pinzón MA.  J Cereb Blood Flow Metab.  2004; 24 (6): 636-45
• Preservation of base-line hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C epsilon. Gray MO,  Zhou HZ, Schafhalter-Zoppoth I, Zhu P, Mochly-Rosen D, Messing RO.  J Biol Chem.  2004; 279 (5): 3596-604
• Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Murriel CL,  Mochly-Rosen D.  Arch Biochem Biophys.  2003; 420 (2): 246-54
• Opposing effects of delta- and zeta-protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors. Braun MU,  Mochly-Rosen D.  J Mol Cell Cardiol.  2003; 35 (8): 895-903
• PKC isozyme selective regulation of cloned human cardiac delayed slow rectifier K current. Xiao GQ,  Mochly-Rosen D, Boutjdir M.  Biochem Biophys Res Commun.  2003; 306 (4): 1019-25
• Epsilon PKC is required for the induction of tolerance by ischemic and NMDA-mediated preconditioning in the organotypic hippocampal slice. Raval AP,  Dave KR, Mochly-Rosen D, Sick TJ, Pérez-Pinzón MA.  J Neurosci.  2003; 23 (2): 384-91
• Prevention of NMDA-induced death of cortical neurons by inhibition of protein kinase Czeta. Koponen S,  Kurkinen K, Akerman KE, Mochly-Rosen D, Chan PH, Koistinaho J.  J Neurochem.  2003; 86 (2): 442-50
• Cytotoxicity of pEGFP vector is due to residues encoded by multiple cloning site. Endemann G,  Schechtman D, Mochly-Rosen D.  Anal Biochem.  2003; 313 (2): 345-7
• Methods for detecting binding proteins: an introduction. Endemann G,  Mochly-Rosen D.  Methods Mol Biol.  2003; 233 307-25
• Glutathione S-transferase pull-down assay. Schechtman D,  Mochly-Rosen D, Ron D.  Methods Mol Biol.  2003; 233 345-50
• Overlay method for detecting protein-protein interactions. Schechtman D,  Murriel C, Bright R, Mochly-Rosen D.  Methods Mol Biol.  2003; 233 351-7
• The betagamma subunit of heterotrimeric G proteins interacts with RACK1 and two other WD repeat proteins. Dell EJ,  Connor J, Chen S, Stebbins EG, Skiba NP, Mochly-Rosen D, Hamm HE.  J Biol Chem.  2002; 277 (51): 49888-95
• Isozyme-specific abnormalities of PKC in thyroid cancer: evidence for post-transcriptional changes in PKC epsilon. Knauf JA,  Ward LS, Nikiforov YE, Nikiforova M, Puxeddu E, Medvedovic M, Liron T, Mochly-Rosen D, Fagin JA.  J Clin Endocrinol Metab.  2002; 87 (5): 2150-9
• Dopamine-induced exocytosis of Na,K-ATPase is dependent on activation of protein kinase C-epsilon and -delta. Ridge KM,  Dada L, Lecuona E, Bertorello AM, Katz AI, Mochly-Rosen D, Sznajder JI.  Mol Biol Cell.  2002; 13 (4): 1381-9
• Sequential activation of individual PKC isozymes in integrin-mediated muscle cell spreading: a role for MARCKS in an integrin signaling pathway. Disatnik MH,  Boutet SC, Lee CH, Mochly-Rosen D, Rando TA.  J Cell Sci.  2002; 115 (Pt 10): 2151-63
• Isozyme-specific inhibitors and activators of protein kinase C. Schechtman D,  Mochly-Rosen D.  Methods Enzymol.  2002; 345 470-89
• Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Jin ZQ,  Zhou HZ, Zhu P, Honbo N, Mochly-Rosen D, Messing RO, Goetzl EJ, Karliner JS, Gray MO.  Am J Physiol Heart Circ Physiol.  2002; 282 (6): H1970-7
• Intracellular transport mechanisms of signal transducers. Dorn GW,  Mochly-Rosen D.  Annu Rev Physiol.  2002; 64 407-29
• Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta. Inagaki K,  Iwanaga Y, Sarai N, Onozawa Y, Takenaka H, Mochly-Rosen D, Kihara Y.  J Mol Cell Cardiol.  2002; 34 (10): 1377-85
• Spontaneous occurrence of an inhibitor of protein kinase C localization in a thyroid cancer cell line: role in thyroid tumorigenesis. Mochly-Rosen D,  Fagin JA, Knauf JA, Nikiforov Y, Liron T, Schechtman D.  Adv Enzyme Regul.  2001; 41 87-97
• Arachidonic acid protects neonatal rat cardiac myocytes from ischaemic injury through epsilon protein kinase C. Mackay K,  Mochly-Rosen D.  Cardiovasc Res.  2001; 50 (1): 65-74
• Opposing effects of delta and xi PKC in ethanol-induced cardioprotection. Chen C,  Mochly-Rosen D.  J Mol Cell Cardiol.  2001; 33 (3): 581-5
• Adaptor proteins in protein kinase C-mediated signal transduction. Schechtman D,  Mochly-Rosen D.  Oncogene.  2001; 20 (44): 6339-47
• Evidence for functional role of epsilonPKC isozyme in the regulation of cardiac Na(+) channels. Xiao GQ,  Qu Y, Sun ZQ, Mochly-Rosen D, Boutjdir M.  Am J Physiol Cell Physiol.  2001; 281 (5): C1477-86
• Localization, anchoring, and functions of protein kinase C isozymes in the heart. Mackay K,  Mochly-Rosen D.  J Mol Cell Cardiol.  2001; 33 (7): 1301-7
• Involvement of a p38 mitogen-activated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia. Mackay K,  Mochly-Rosen D.  J Mol Cell Cardiol.  2000; 32 (8): 1585-8
• Protein kinase C isozymes and the regulation of diverse cell responses. Dempsey EC,  Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO.  Am J Physiol Lung Cell Mol Physiol.  2000; 279 (3): L429-38
• Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C. Aley KO,  Messing RO, Mochly-Rosen D, Levine JD.  J Neurosci.  2000; 20 (12): 4680-5
• Evidence for functional role of epsilonPKC isozyme in the regulation of cardiac Ca(2+) channels. Hu K,  Mochly-Rosen D, Boutjdir M.  Am J Physiol Heart Circ Physiol.  2000; 279 (6): H2658-64
• Pharmacological regulation of network kinetics by protein kinase C localization. Mochly-Rosen D,  Kauvar LM.  Semin Immunol.  2000; 12 (1): 55-61
• Characterization of the binding and phosphorylation of cardiac calsequestrin by epsilon protein kinase C. Rodriguez MM,  Chen CH, Smith BL, Mochly-Rosen D.  FEBS Lett.  1999; 454 (3): 240-6
• RACK1, a protein kinase C anchoring protein, coordinates the binding of activated protein kinase C and select pleckstrin homology domains in vitro. Rodriguez MM,  Ron D, Touhara K, Chen CH, Mochly-Rosen D.  Biochemistry.  1999; 38 (42): 13787-94
• An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. Mackay K,  Mochly-Rosen D.  J Biol Chem.  1999; 274 (10): 6272-9
• Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Csukai M,  Mochly-Rosen D.  Pharmacol Res.  1999; 39 (4): 253-9
• Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. Knauf JA,  Elisei R, Mochly-Rosen D, Liron T, Chen XN, Gonsky R, Korenberg JR, Fagin JA.  J Biol Chem.  1999; 274 (33): 23414-25
• Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes. Liu GS,  Cohen MV, Mochly-Rosen D, Downey JM.  J Mol Cell Cardiol.  1999; 31 (10): 1937-48
• Anchoring proteins for protein kinase C: a means for isozyme selectivity. Mochly-Rosen D,  Gordon AS.  FASEB J.  1998; 12 (1): 35-42
• Molecular genetic approaches. II. Expression-interaction cloning. Csukai M,  Mochly-Rosen D.  Methods Mol Biol.  1998; 88 133-9
• Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis. Laudanna C,  Mochly-Rosen D, Liron T, Constantin G, Butcher EC.  J Biol Chem.  1998; 273 (46): 30306-15
• Activation of epsilon protein kinase C correlates with a cardioprotective effect of regular ethanol consumption. Miyamae M,  Rodriguez MM, Camacho SA, Diamond I, Mochly-Rosen D, Figueredo VM.  Proc Natl Acad Sci U S A.  1998; 95 (14): 8262-7
• Modulating protein kinase C signal transduction. Mochly-Rosen D,  Kauvar LM.  Adv Pharmacol.  1998; 44 91-145
• An inhibitory fragment derived from protein kinase Cepsilon prevents enhancement of nerve growth factor responses by ethanol and phorbol esters. Hundle B,  McMahon T, Dadgar J, Chen CH, Mochly-Rosen D, Messing RO.  J Biol Chem.  1997; 272 (23): 15028-35
• Translocation inhibitors define specificity of protein kinase C isoenzymes in pancreatic beta-cells. Yedovitzky M,  Mochly-Rosen D, Johnson JA, Gray MO, Ron D, Abramovitch E, Cerasi E, Nesher R.  J Biol Chem.  1997; 272 (3): 1417-20
• C2 region-derived peptides of beta-protein kinase C regulate cardiac Ca2+ channels. Zhang ZH,  Johnson JA, Chen L, El-Sherif N, Mochly-Rosen D, Boutjdir M.  Circ Res.  1997; 80 (5): 720-9
• The HIV nef protein associates with protein kinase C theta. Smith BL,  Krushelnycky BW, Mochly-Rosen D, Berg P.  J Biol Chem.  1996; 271 (28): 16753-7
• Differential activation of protein kinase C isozymes by phorbol ester and collagen in human skin microvascular endothelial cells. Zhou LY,  Disatnik M, Herron GS, Mochly-Rosen D, Karasek MA.  J Invest Dermatol.  1996; 107 (2): 248-52
• A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. Johnson JA,  Gray MO, Chen CH, Mochly-Rosen D.  J Biol Chem.  1996; 271 (40): 24962-6
• An improved permeabilization protocol for the introduction of peptides into cardiac myocytes. Application to protein kinase C research. Johnson JA,  Gray MO, Karliner JS, Chen CH, Mochly-Rosen D.  Circ Res.  1996; 79 (6): 1086-99
• Signal transduction by the polymeric immunoglobulin receptor suggests a role in regulation of receptor transcytosis. Cardone MH,  Smith BL, Mennitt PA, Mochly-Rosen D, Silver RB, Mostov KE.  J Cell Biol.  1996; 133 (5): 997-1005
• Stimulus-dependent subcellular localization of activated protein kinase C; a study with acidic fibroblast growth factor and transforming growth factor-beta 1 in cardiac myocytes. Disatnik MH,  Jones SN, Mochly-Rosen D.  J Mol Cell Cardiol.  1995; 27 (11): 2473-81
• The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor. Brzoska PM,  Chen H, Zhu Y, Levin NA, Disatnik MH, Mochly-Rosen D, Murnane JP, Christman MF.  Proc Natl Acad Sci U S A.  1995; 92 (17): 7824-8
• Prolonged phorbol ester treatment down-regulates protein kinase C isozymes and increases contraction rate in neonatal cardiac myocytes. Johnson JA,  Adak S, Mochly-Rosen D.  Life Sci.  1995; 57 (11): 1027-38
• Inhibition of the spontaneous rate of contraction of neonatal cardiac myocytes by protein kinase C isozymes. A putative role for the epsilon isozyme. Johnson JA,  Mochly-Rosen D.  Circ Res.  1995; 76 (4): 654-63
• Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction. Mochly-Rosen D,  Smith BL, Chen CH, Disatnik MH, Ron D.  Biochem Soc Trans.  1995; 23 (3): 596-600
• C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo. Ron D,  Luo J, Mochly-Rosen D.  J Biol Chem.  1995; 270 (41): 24180-7
• Distinct responses of protein kinase C isozymes to c-erbB-2 activation in SKBR-3 human breast carcinoma cells. Disatnik MH,  Winnier AR, Mochly-Rosen D, Arteaga CL.  Cell Growth Differ.  1994; 5 (8): 873-80
• Agonists and antagonists of protein kinase C function, derived from its binding proteins. Ron D,  Mochly-Rosen D.  J Biol Chem.  1994; 269 (34): 21395-8
• Phospholipase C-gamma 1 binding to intracellular receptors for activated protein kinase C. Disatnik MH,  Hernandez-Sotomayor SM, Jones G, Carpenter G, Mochly-Rosen D.  Proc Natl Acad Sci U S A.  1994; 91 (2): 559-63
• Phorbol myristate acetate-mediated stimulation of transcytosis and apical recycling in MDCK cells. Cardone MH,  Smith BL, Song W, Mochly-Rosen D, Mostov KE.  J Cell Biol.  1994; 124 (5): 717-27
• Developmental expression of protein kinase C subspecies in rat brain-pituitary axis. Garcia-Navarro S,  Marantz Y, Eyal R, Kalina M, Disatnik MH, Mochly-Rosen D, Ben-Menahem D, Reiss N, Naor Z.  Mol Cell Endocrinol.  1994; 103 (1-2): 133-8
• p65 fragments, homologous to the C2 region of protein kinase C, bind to the intracellular receptors for protein kinase C. Mochly-Rosen D,  Miller KG, Scheller RH, Khaner H, Lopez J, Smith BL.  Biochemistry.  1992; 31 (35): 8120-4
• Nicotinic acetylcholine receptor desensitization is regulated by activation-induced extracellular adenosine accumulation. Pitchford S,  Day JW, Gordon A, Mochly-Rosen D.  J Neurosci.  1992; 12 (11): 4540-4
• The role of adenosine and adenosine transport in ethanol-induced cellular tolerance and dependence. Possible biologic and genetic markers of alcoholism. Diamond I,  Nagy L, Mochly-Rosen D, Gordon A.  Ann N Y Acad Sci.  1991; 625 473-87
• Identification of intracellular receptor proteins for activated protein kinase C. Mochly-Rosen D,  Khaner H, Lopez J.  Proc Natl Acad Sci U S A.  1991; 88 (9): 3997-4000
• The identification and purification of a mammalian-like protein kinase C in the yeast Saccharomyces cerevisiae. Simon AJ,  Milner Y, Saville SP, Dvir A, Mochly-Rosen D, Orr E.  Proc Biol Sci.  1991; 243 (1307): 165-71
• GTP-binding proteins are restricted to signal transduction sites. Mochly-Rosen D,  Gordon AS.  Biochem Biophys Res Commun.  1990; 173 (1): 388-95
• Chronic ethanol-induced heterologous desensitization is mediated by changes in adenosine transport. Gordon AS,  Nagy L, Mochly-Rosen D, Diamond I.  Biochem Soc Symp.  1990; 56 117-36
• A protein kinase C isozyme is translocated to cytoskeletal elements on activation. Mochly-Rosen D,  Henrich CJ, Cheever L, Khaner H, Simpson PC.  Cell Regul.  1990; 1 (9): 693-706
• A general procedure for screening inhibitory antibodies: application for identifying anti-protein kinase C antibodies. Mochly-Rosen D,  Koshland DE.  Anal Biochem.  1988; 170 (1): 31-7
• Distinct cellular and regional localization of immunoreactive protein kinase C in rat brain. Mochly-Rosen D,  Basbaum AI, Koshland DE.  Proc Natl Acad Sci U S A.  1987; 84 (13): 4660-4
• Exposure of HeLa DNA polymerase alpha to protein kinase C affects its catalytic properties. Krauss SW,  Mochly-Rosen D, Koshland DE, Linn S.  J Biol Chem.  1987; 262 (8): 3432-5
• Comparison of S100b protein with calmodulin: interactions with melittin and microtubule-associated tau proteins and inhibition of phosphorylation of tau proteins by protein kinase C. Baudier J,  Mochly-Rosen D, Newton A, Lee SH, Koshland DE, Cole RD.  Biochemistry.  1987; 26 (10): 2886-93
• Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. Bollag GE,  Roth RA, Beaudoin J, Mochly-Rosen D, Koshland DE.  Proc Natl Acad Sci U S A.  1986; 83 (16): 5822-4
• Antigenic specificity of acetylcholine receptor in developing muscle. Studies with monoclonal antibodies. Souroujon MC,  Pizzighella S, Mochly-Rosen D, Fuchs S.  J Neuroimmunol.  1985; 8 (2-3): 159-66
• Interaction of monoclonal antibodies to Torpedo acetylcholine receptor with the receptor of skeletal muscle. Souroujon MC,  Mochly-Rosen D, Gordon AS, Fuchs S.  Muscle Nerve.  1983; 6 (4): 303-11
• An anti-acetylcholine receptor monoclonal antibody cross-reacts with phosvitin. Pizzighella S,  Gordon AS, Souroujon MC, Mochly-Rosen D, Sharp A, Fuchs S.  FEBS Lett.  1983; 159 (1-2): 246-50
• Monoclonal antibodies modify acetylcholine-induced ionic channel properties in cultured chick myoballs. Goldberg G,  Mochly-Rosen D, Fuchs S, Lass Y.  J Membr Biol.  1983; 76 (2): 123-8
• Molecular aspects of experimental autoimmune myasthenia gravis. Fuchs S,  Bartfeld D, Mochly-Rosen D, Schmidt-Hopfeld I, Tarrab-Hazdai R.  Prog Clin Biol Res.  1981; 63 405-17
• Acetylcholine receptor: molecular dissection and monoclonal antibodies in the study of experimental myasthenia. Fuchs S,  Bartfeld D, Mochly-Rosen D, Souroujon M, Feingold C.  Ann N Y Acad Sci.  1981; 377 110-24
• Immune regulation of experimental myasthenia. Fuchs S,  Bartfeld D, Eshhar Z, Feingold C, Mochly-Rosen D, Novick D, Schwartz M, Tarrab-Hazdai R.  J Neurol Neurosurg Psychiatry.  1980; 43 (7): 634-43
• Modification of acetylcholine receptor: chemical and immunological characterization of polyalanyl acetylcholine receptor. Tarrab-Hazdai R,  Schmidt-Sole Y, Mochly-Rosen D, Fuchs S.  FEBS Lett.  1980; 118 (1): 35-8